688076 ST诺泰生物
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)4.24411.78416.7568.0456.976
总资产报酬率 ROA (%)1.9105.6279.3815.3965.563
投入资产回报率 ROIC (%)2.1426.28210.3075.9116.031

边际利润分析
销售毛利率 (%)61.96662.64467.68560.97057.573
营业利润率 (%)27.18321.03327.58618.35118.978
息税前利润/营业总收入 (%)31.37121.53128.12317.87218.693
净利润/营业总收入 (%)22.94716.74924.60716.00818.687

收益指标分析
经营活动净收益/利润总额(%)116.259128.491112.187119.14384.864
价值变动净收益/利润总额(%)0.3400.976-0.3931.82614.765
营业外收支净额/利润总额(%)0.109-13.356-2.215-9.553-1.389

偿债能力分析
流动比率 (X)1.1701.1611.1441.5361.909
速动比率 (X)0.7470.7640.8111.1481.322
资产负债率 (%)54.08655.46647.21438.32423.931
带息债务/全部投入资本 (%)45.13245.78038.08529.95515.346
股东权益/带息债务 (%)112.937109.180151.307223.701538.466
股东权益/负债合计 (%)84.52079.858110.885159.534315.406
利息保障倍数 (X)7.5447.23524.77815.938-744.597

营运能力分析
应收账款周转天数 (天)83.93895.64991.71594.33499.796
存货周转天数 (天)376.320358.030329.524312.642374.107